Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05336838
Other study ID # RECHMPL21_0729
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 1, 2022
Est. completion date May 1, 2023

Study information

Verified date April 2022
Source University Hospital, Montpellier
Contact Jessie Grenié, MD
Phone 00330467336472
Email j-grenie@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Post partum haemorrhage is a concerning situation in maternity wards, though it is not the first cause of maternal mortality anymore. It has been already shown that low fibrinogen level is a major predictive factor of massive bleeding after delivery. In this situation, the early knowledge of fibrinogen level could enhance care of women experiencing post partum haemorrhage. In a cohort of women suffering from post partum haemorrhage, this study will evaluate whether assessing fibrinogen level would be faster using the Quantra® system than the standard coagulation test.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date May 1, 2023
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: Women = 18 years old Experiencing post partum haemorrhage = 500 mL Within 24 hours after delivery Exclusion Criteria: - Previous anemia = 7g/dL - Known bleeding disorders - Ongoing antiplatelets treatment - Ongoing anticoagulant treatment

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of delay in obtaining Quantra Fibrinogen Clot Stiffness result to standard fibrinogen level result Comparison of delay in obtaining Quantra Fibrinogen Clot Stiffness result to standard fibrinogen level result When post partum haemorrhage occurred, within 24 hours after delivery
Secondary Comparison of level of fibrinogen assessed by Quantra Fibrinogen Clot Stiffness to level of fibrinogen assessed by standard coagulation test Fibrinogen level assessed by Quantra and standard coagulation tests When post partum haemorrhage occurred, within 24 hours after delivery
Secondary Comparison of Quantra Clot Time result to Standard Kaolin Clotting time result Coagulation function assessed by Quantra and standard coagulation tests When post partum haemorrhage occurred, within 24 hours after delivery
Secondary Comparison of Platelet Clot Stiffness result to standard platelet count result Platelet function assessed by Quantra and standard platelet count. When post partum haemorrhage occurred, within 24 hours after delivery
Secondary Rate of satisfaction of anesthetist in charge of patient assessed by Lickert scale Rate of satisfaction of anesthetist in charge of patient assessed by Lickert scale [1-Strongly disagree ; 2-Disagree ; 3-Neither agree nor disagree ; 4-Agree ; 5-Strongly agree When post partum haemorrhage occurred, within 24 hours after delivery
See also
  Status Clinical Trial Phase
Recruiting NCT02303418 - Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial Phase 3
Recruiting NCT00344929 - Severe Post Partum Haemorrhage (PPH): A Randomized Trial on Transversal Intervention in 6 French Perinatal Networks N/A
Completed NCT02775773 - Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH Phase 3
Completed NCT02216383 - Intramuscular Oxytocics: A Randomised Control Trial Phase 3
Completed NCT01571323 - Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section Phase 1/Phase 2
Terminated NCT02908126 - Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility Phase 1
Terminated NCT02900690 - Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy